Navigation Links
Yasmin, Yaz Alleged Blood-Clotting Lawsuits Update: Resource4thePeople Reports Bayer Settles Nearly 5,000 Cases for $1 Billion and also now Settling Gall Bladder Cases
Date:4/27/2013

tting side effects:

“The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.”

In its announcement the FDA said that “The revised drug labels (Beyaz, Safyral, Yasmin and Yaz) will report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone-containing products. The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.”

Resource4thePeople said that additional inquiries about Yasmin and Yaz claims are coming in over news about a controversial Canadian case.

As reported by the Canadian Broadcasting Company (CBC) the British Columbia coroner’s office refused an autopsy request by the family of a woman who died from blood clots after being prescribed Yasmin.*****

The family then spent $1,200 out of their own pockets and their pathologist found that Yasmin and the woman’s obesity put her at risk of suffering the fatal blood clots, according to the report.*****

“According to the CBC the victim’s family is now seeking legal advice to determine whether they will join in the litigation against the manufacturers of Yasmin,” said Resource4thePeople. “This case involves similar
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
2. Multiple Vaginal Mesh Lawsuits Filed Against Ethicon, Inc. on Behalf of Women Seriously Injured Allegedly Due to Vaginal Mesh Sling Defects, Reports Wright & Schulte
3. Lipitor Diabetes Lawsuit Filed by South Carolina Woman Who Developed Type 2 Diabetes Allegedly Due to Lipitor Use, Alonso Krangle Investigating
4. In Light of Alleged Deceptive Marketing Claims Made by Drug Makers, Parker Waichman LLP Addresses Issues Allegedly Related to the Safety and Effectiveness of Plavix
5. Skechers Fracture Lawsuit Filed on Behalf of an Arizona Woman Who Sustained Multiple Arm Fractures Allegedly Due to Unstable Shape-Ups, by Wright & Schulte
6. Vaginal Mesh Lawsuit Filed by Wright & Schulte Claims Nebraska Woman Sustained Painful Injuries Allegedly Due to Defective Vaginal Mesh Implants
7. Skechers Injury Lawsuits Filed By Wright & Schulte on Behalf of Two Consumers Who Sustained Serious Knee Injuries Allegedly Due to Wearing Shape-Ups
8. TransVaginal Mesh Lawsuit Filed on Behalf of a Georgia Woman Seriously Injured Allegedly Due to Defective TransVaginal Mesh Implants, Reports Wright & Schulte
9. Six Skechers Broken Bones Lawsuits Filed on Behalf of Consumers Who Sustained Various Bone Breaks / Fractures Allegedly Due to Design of Shape-Ups, by Wright & Schulte
10. Skechers Injury Lawsuit Filed on Behalf of a Mississippi Woman Who Suffered a Serious Knee Injury Allegedly Due to Shape-Ups’ Defective Design, by Wright & Schulte LLC
11. Multiple Skechers Lawsuits Filed on Behalf of Five Consumers Who Suffered Serious Ankle Fractures Allegedly Due to Wearing Shape-Ups, by Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Columbia, SC (PRWEB) September 02, 2014 The ... an outreach fair and public town hall meeting for Veterans ... be available at the outreach fair to provide Veterans with ... B. McMurry. “The town hall will provide a forum where ... our VA programs.” , The outreach fair will be held ...
(Date:9/2/2014)... early-stage breast cancer in California, the percentage undergoing a ... this procedure was not associated with a lower risk ... a study in the September 3 issue of ... the removal of one breast was associated with a ... in the study. , Randomized trials have demonstrated similar ...
(Date:9/2/2014)... Medex Analytic Services is delighted to announce the ... Fla. due to their greater than forecasted growth. , ... 2014 year by distinguishing Medex in the industry,” said ... level of service and professionalism in the delivery of ... has responded.” , The location of the new ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Two new ... One suggests that 6-year-olds who were breast-fed have a ... to bottle-fed infants, while the other finds a similar ... upholds the "many benefits of breast-feeding in the immediate ... Lenox Hill Hospital in New York City. She was ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... News) --,Concentrating on music can provide enough distraction to ... to a new study. Researchers from the University ... music as a pain reliever on 143 study participants. ... they could identify the tones that stood out. While ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- ... crushing depression and crippling anxiety to powerful delusions and hallucinations ... the imagined. And if that weren,t enough, they also ... world perceives their inner struggle. Stigma associated with ...
... In some cases, memory loss among the elderly may be ... strokes, which may not cause any noticeable symptoms, result in ... roughly 25 percent of older adults, the study team noted. ... in the elderly is that it examines silent strokes and ...
... , WEDNESDAY, Dec. 28 (HealthDay News) -- Two new ... by about four months for women with ovarian cancer. ... make a difference in overall survival. One study suggested it ... overall survival between two treatment groups. "The bottom-line results ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... Dec. 29, 2011) Treating ovarian cancer with the drug ... show the results of an international clinical trial co-led by ... Health Network and Timothy Perren, St James,s Institute of Oncology, ... New England Journal of Medicine, report that the ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2
(Date:9/2/2014)... September 2, 2014   ... atrial muestran agentes antitrombóticos no utilizados óptimamente para ... -- Las presentaciones de GARFIELD-AF en el ESC ... y los resultados de pacientes en riesgo de ...    Los datos de casi 12.500 ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... /PRNewswire-USNewswire/ – CoMeD – On Friday, July ... (UNEP) distributed a revised text for its comprehensive ... were gratified to see pharmaceuticals listed in "Annex C ... The Coalition for Mercury-free Drugs (CoMeD) ...
... Reportlinker.com announces that a new market ... Sustained Release Injectables: Evolving ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... to increase the duration of efficacy for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: